Page 12 - Maureen Mcenroe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Marizyme Announces Approval for DuraGraft® in India

Marizyme Announces Approval for DuraGraft® in India Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021 News provided by Share this article Share this article JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft ® is now registered and licensed for import into India through Marizyme s distribution partner Regency Lifesciences. India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries. Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide approvals pending.

United statesIngrid mezoAbel alexanderMaureen mcenroeMiriam millerNeil campbellIndian healthMarizyme incRegency lifesciencesArtery bypass graft surgeriesMyocardial infarctionRepeat revascularizationMajor adverse cardiac eventsLeading distributorHealthcare devicesHealth care amp hospitals

Marizyme, Inc to Present at Biotech Showcase 2021 During the J P Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During J P Morgan Week 2021

Registration: https://informaconnect.com/biotech-showcase/registration-options/ During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft , an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase

Ingrid mezoKostenloser wertpapierhandelMaureen mcenroeMiriam millerNeilj campbellTiberend strategic advisors incExchange commissionPrnewswire marizyme incMarizyme incChief executive officerBiotech showcase digitalBiotech showcaseMyocardial infarctionRepeat revascularizationStrategic advisorsமவ்ரீன் அம்கெந்ரொ

Marizyme, Inc to Present at Biotech Showcase 2021 During the J P Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During J P Morgan Week 2021

During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft ®, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase

Ingrid mezoMaureen mcenroeMiriam millerNeilj campbellExchange commissionMarizyme incChief executive officerBiotech showcase digitalBiotech showcaseMyocardial infarctionRepeat revascularizationமவ்ரீன் அம்கெந்ரொமிரியம் மில்லர்பரிமாற்றம் தரகுதலைமை நிர்வாகி அதிகாரிபயோடெக் காட்சி பெட்டி டிஜிட்டல்

Börse Express - Marizyme, Inc wird während der J P Morgan Healthcare Conference Biotech Showcase Digital an der Biotech Showcase 2021 und während der J P Morgan Week 2021 an der BIO @ JPM teilnehmen

Börse Express - Marizyme, Inc wird während der J P Morgan Healthcare Conference Biotech Showcase Digital an der Biotech Showcase 2021 und während der J P Morgan Week 2021 an der BIO @ JPM teilnehmen
boerse-express.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-express.com Daily Mail and Mail on Sunday newspapers.

United statesMiriam millerMaureen mcenroeBiotech showcaseChief executiveMember drcBiotech showcase digitalJpm willJpm dateBiotechnology showcase digitalBiotechnology will showcaseCampbell virtualAsian countriesAbout cabgPatients undergoIschaemic protects

Marizyme, Inc wird während der J P Morgan Healthcare Conference Biotech Showcase Digital an der Biotech Showcase 2021 und während der J P Morgan Week 2021 an der BIO @ JPM teilnehmen

Marizyme, Inc wird während der J P Morgan Healthcare Conference Biotech Showcase Digital an der Biotech Showcase 2021 und während der J P Morgan Week 2021 an der BIO @ JPM teilnehmen
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesIngrid mezoMiriam millerMaureen mcenroeBiotech showcaseChief executiveMember drcBiotech showcase digitalJpm willJpm dateBiotechnology showcase digitalBiotechnology will showcaseCampbell virtualAsian countriesAbout cabgPatients undergo